Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ519,55200,29
KB0,12
PKN86,1286,140,77
Msft0,56
Nokia3,74453,75-0,91
IBM0,24
Daimler AG46,68546,695-0,39
PFE-0,25
18.01.2020 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 17.01.2020
Arseus (RCUS.BR, Brussels)
Závěr k 17.1.2020 Změna (%) Změna (EUR) Objem obchodů (EUR)
20,06 -0,89 -0,18 2 262 006
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.01.2020
Popis společnosti
Obecné informace
Název společnostiFagron NV
TickerFAGR
Kmenové akcie:Ordinary Shares
RICFAGRO.BR
ISINBE0003874915
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.09.2019
Počet zaměstnanců k 31.12.2018 2 488
Akcie v oběhu k 30.06.2019 71 740 277
MěnaEUR
Kontaktní informace
UliceVenecoweg 20A
MěstoNAZARETH
PSČ9810
ZeměBelgium
Kontatní osoba 
Funkce kontaktní osoby 
Telefon3 280 012 880
Fax3292162491

Business Summary: Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Fagron NV revenues increased 11% to EUR255.4M. Net income applicable to common stockholders excluding extraordinary items increased 43% to EUR26.5M. Revenues reflect Fagron North America segment increase of 37% to EUR69.9M, Fagron South America segment increase of 7% to EUR52.4M. Net income benefited from Financial expenses decrease of 30% to EUR7.7M (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Pharmaceuticals - NEC
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 20.01.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Board representing AHOK BVBAKoen Hoffman5108.05.201708.05.2017
Chief Executive Officer, Member of the Executive Committee, DirectorRafael Padilla4127.11.2017
Chief Financial Officer, Executive Director, Member of the Executive CommitteeKarin de Jong4008.05.2017
Chief Communications Officer, Member of the Executive CommitteeConstantijn van Rietschoten49